Synergistic cancer cell cytotoxicity of TLK286 (TELCYTA™) in combination with carboplatin, cisplatin, doxorubicin, docetaxel, paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal cancer cell lines.

被引：0
|
作者：
Xu, H [1 ]
Namgoong, SY [1 ]
Roth, E [1 ]
Tran, V [1 ]
Schow, S [1 ]
Brown, GL [1 ]
Keck, JG [1 ]
机构：
[1] Telik Inc, Palo Alto, CA USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6241S / 6242S
页数：2
相关论文
共 50 条
  • [1] Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines
    Keck, J
    Meng, F
    Grossman, E
    Cai, D
    Brown, G
    Schow, S
    Xu, H
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S35 - S35
  • [2] Synergistic cytotoxicity of metformin cotreatment with paclitaxel or carboplatin in triple negative breast cancer cell lines.
    Longoria, Ossian
    Esparza Lopez, Jose
    Leon-Rodriguez, Eucario
    de Jesus Ibarra-Sanchez, Maria
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [3] Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Sequist, L
    Fidias, P
    Temel, J
    Kennedy, E
    Ostler, P
    Rabin, M
    Huberman, M
    Keck, J
    Brown, G
    Lynch, T
    [J]. LUNG CANCER, 2005, 49 : S269 - S269
  • [4] Phase 1-2a dose ranging study of TLK286 (Telcyta™, a novel gluthathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
    Papaclimitrakopoulou, V
    Zinner, R
    Blumenschein, G
    King, L
    Boasberg, P
    Keck, J
    Mascavage, J
    Jameson, A
    Patel, K
    Parra, R
    Brown, GL
    Hanna, N
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6241S - 6241S
  • [5] Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines
    Vijayalakshmi N. Ayyagari
    Tsung-han Jeff Hsieh
    Paula L. Diaz-Sylvester
    Laurent Brard
    [J]. BMC Cancer, 17
  • [6] Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines
    Ayyagari, Vijayalakshmi N.
    Hsieh, Tsung-han Jeff
    Diaz-Sylvester, Paula L.
    Brard, Laurent
    [J]. BMC CANCER, 2017, 17
  • [7] Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines
    Ayyagari, Vijayalakshmi N.
    Diaz-Sylvester, Paula L.
    Hsieh, Tsung-han Jeff
    Brard, Laurent
    [J]. PLOS ONE, 2017, 12 (09):
  • [8] Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC)
    Papadimitrakopoulou, V
    Edelman, M
    Zinner, R
    Blumenschein, G
    Jones, S
    Willcutt, N
    Keck, J
    Brown, G
    Burris, H
    [J]. LUNG CANCER, 2005, 49 : S262 - S263
  • [9] Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
    Serova, M
    Calvo, F
    Lokiec, F
    Koeppel, F
    Poindessous, V
    Larsen, AK
    Van Laar, ES
    Waters, SJ
    Cvitkovic, E
    Raymond, E
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) : 491 - 499
  • [10] Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
    Maria Serova
    Fabien Calvo
    François Lokiec
    Florence Koeppel
    Virginie Poindessous
    Annette K. Larsen
    Emily S. Van. Laar
    Stephen J. Waters
    Esteban Cvitkovic
    Eric Raymond
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 57 : 491 - 499
12345